Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Brain Cancer treatment details. Biologic therapy. MD Anderson Cancer Center, Houston, TX, United States



Survival: 9.7 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
   
Drugs:
Country: United States
   
City/State/Province: Houston, TX
   
Hospital: MD Anderson Cancer Center
   
Journal: Link
   
Date: 7/2010

Description:
Patients:
This phase II study involved 48 patients with first-relapse glioblastoma. The median age of the patients was 51 years (range 37-73). Gender distribution was not reported.

Treatment:
Patients in this study were treated with a biologic therapy called erlotinib (trade name Tarceva; made by Genentech, Inc.). Erlotinib is a small molecular inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in cell growth and survival.

Toxicities:
One death related to treatment (due to sepsis) was reported in this study. Also, grade 3 or 4 diarrhea or rash was experienced by 4% and 18.8% of the patients, respectively.

Results:
Median overall survival in this study was 9.7 months.

Support:
This study was partially funded by Genentech, Inc., the makers of erlotinib.

Correspondence: Dr. W. K. Alfred Yung; email: wyung@mdanderson.org

E-mail to a Friend Email Physician More Information